sarcopenia glp 1 Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do Weighing the risk of GLP-1

Diabetologia (2016) 59(5):105969

The pathological mechanism might be the dysregulation of glucose metabolism, which triggered the accumulation of epicardial adipose tissue (EAT) and free fatty acids in heart, leading to myocardial lipotoxicity, oxidative stress, and mitochondrial dysfunction [41]

Third, the long-term permanence and clinical relevance of biomarker changes are still unknown, and the majority of studies had comparatively short follow-up (median 1226 weeks)

your daily choices determine how far you go with it

Advanced Delivery Systems and Formulation Technologies The current standard is a subcutaneous shot, but new mouth delivery systems are being developed that could make the market much more accessible